Portage Biotech Inc.(PRTG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRTG Portage Biotech Inc.

Not Yet Opened 09-03 16:00:00 EDT

6.81

+0.00

0.00%

High6.81	Low6.81	Vol0.00
Open6.81	D1 Closing6.81	Amplitude0.00%
Mkt Cap15.52M	Tradable Cap9.77M	Total Shares2.28M
T/O3.13M	T/O Rate0.00%	Tradable Shares1.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRTG","market":"US","secType":"STK","nameCN":"Portage Biotech Inc.","latestPrice":6.81,"timestamp":1756929600000,"preClose":6.81,"halted":8,"volume":0,"delay":0,"floatShares":1434800,"shares":2278622,"eps":-5.720202,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-03 16:00:00 EDT","open":6.81,"high":6.81,"low":6.81,"amount":3129594.1139579997,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.720202,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":0,"symbolChange":{"newSymbol":"ATON","executeDate":"2025-09-04"},"adr":0,"exchange":"NASDAQ","adjPreClose":6.81,"volumeRatio":0},"requestUrl":"/m/hq/s/PRTG","defaultTab":"news","newsList":[{"id":"2564318732","title":"AlphaTON Capital Establishes Specialized Digital Asset Treasury Company; Appoints Brittany Kaiser as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2564318732","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564318732?lang=en_us&edition=fundamental","pubTime":"2025-09-04 01:35","pubTimestamp":1756920927,"startTime":"0","endTime":"0","summary":"AlphaTON Capital (PRTG), formerly known as Portage Biotech, said Wednesday it has established a specialized digital asset treasury company and secured financing to acquire about $100 million in TON to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US2Y.BOND","US30Y.BOND","US10Y.BOND","US3Y.BOND","US6M.BOND","US12M.BOND","BK4139","ATON","US7Y.BOND","US5Y.BOND","PRTG"],"gpt_icon":0},{"id":"2564894399","title":"Portage Biotech Inc. Rebrands to AlphaTON Capital Corp, Ticker Changes to \"ATON","url":"https://stock-news.laohu8.com/highlight/detail?id=2564894399","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564894399?lang=en_us&edition=fundamental","pubTime":"2025-09-03 21:22","pubTimestamp":1756905763,"startTime":"0","endTime":"0","summary":"Portage Biotech Inc. has announced a name change to AlphaTON Capital Corp, with a new focus on developing a digital asset treasury strategy for the Telegram ecosystem. The company aims to provide public market access to Toncoin  and leverage Telegram's extensive user base. Brittany Kaiser, a notable figure in digital assets, has been appointed as the new CEO and Board Member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Portage Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDLY7xt5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTG","ATON","BK4139"],"gpt_icon":0},{"id":"2554879416","title":"Press Release: Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2554879416","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554879416?lang=en_us&edition=fundamental","pubTime":"2025-07-26 04:15","pubTimestamp":1753474500,"startTime":"0","endTime":"0","summary":"DOVER, Del., July 25, 2025  -- Portage Biotech Inc.  , a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025.The Company incurred a net loss of approximately $6.8 million during the fiscal year ended March 31, 2025 , which includes approximately $0.2 million of net non-cash expenses. This compares to a net loss of approximately $75.4 million during the fiscal year ended March 31, 2024 , which included approximately $60.9 million of net non-cash expenses. Net loss decreased by approximately $68.6 million year-over-year, which is primarily due to lower non-cash losses attributable to full impairment of the Company's identifiable intangible assets, goodwill, and certain investments as of March 31, 2024.Operating expenses, including research and development  costs and general and a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTG","BK4139"],"gpt_icon":0},{"id":"2546214897","title":"BRIEF-Portage Biotech Regains Full Compliance With Nasdaq Continued Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2546214897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546214897?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:02","pubTimestamp":1750849325,"startTime":"0","endTime":"0","summary":"BRIEF-Portage Biotech Regains Full Compliance With Nasdaq Continued Listing RequirementsJune 25 (Reuters) - Portage Biotech Inc PRTG.O:PORTAGE BIOTECH REGAINS FULL COMPLIANCE WITH NASDAQ CONTINUED LIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUAQ34WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTG","BK4139"],"gpt_icon":0},{"id":"2539295474","title":"Portage Biotech Inc. Announces Change in Certifying Accountant Amid IT Control Weaknesses","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295474","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295474?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:30","pubTimestamp":1748550646,"startTime":"0","endTime":"0","summary":"Portage Biotech Inc. has announced a change in its independent registered accounting firm. On May 29, 2025, Marcum LLP resigned from its role, and CBIZ CPAs P.C. was appointed as the new auditor with the approval of the company's Audit Committee. This change follows CBIZ CPAs' acquisition of Marcum's attest business on November 1, 2024. During the fiscal years ending March 31, 2022, 2023, and 2024, Portage Biotech reported no disagreements with Marcum on accounting principles or practices. However, a material weakness was identified regarding the company's information technology general controls, such as privileged access rights and user access reviews, which could potentially lead to inappropriate financial transactions. These issues were disclosed in the company's annual report and are being addressed to ensure effective financial controls.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL7qHM1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","BK4139","LU2065732104.USD","PRTG","CBZ"],"gpt_icon":0},{"id":"2531787258","title":"Portage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2531787258","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531787258?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:20","pubTimestamp":1745860800,"startTime":"0","endTime":"0","summary":"Shares of Portage Biotech climbed after the company reported confirmatory data for its PORT-7 treatment of mesothelioma, supporting plans for a human trial.The stock rose 21% to $10.23 Monday. Shares have more than doubled over the past 12 months.The clinical stage immuno-oncology company said Monday its PORT-7, a selective adenosine A2B receptor inhibitor, demonstrated superior single agent activity compared with treatment with single agent anti-PD1 antibody in a murine model.Combining both PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone, showing favorable immune response and increases in immune effector cells for mice in the trial, the company said.The treatment is targeted at mesothelioma, an aggressive cancer with limited treatment options.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRTG"],"gpt_icon":0},{"id":"2530140749","title":"Earnings Deluge Eyed as Equity Futures Waver Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2530140749","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530140749?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:57","pubTimestamp":1745845046,"startTime":"0","endTime":"0","summary":"US equity futures were flat before Monday's opening bell as traders stayed on the sidelines ahead of a busy week for corporate earnings.Dow Jones Industrial Average futures were down slightly, S&P 500","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"80632a90d14df15cbc9b2925ce08d3ab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMZN","MSFT","EQR","PRTG","META",".IXIC","KO",".SPX",".DJI"],"gpt_icon":1},{"id":"2530408783","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530408783","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530408783?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:48","pubTimestamp":1745840927,"startTime":"0","endTime":"0","summary":"AmeriServ Financial  shares surged 54% pre-bell Monday on lower-than-average trading volume, following a 3.4% increase on Friday.Portage Biotech  shares advanced nearly 55% after the company said results from a clinical study showed agent activity for its mesothelioma, a cancer drug that was superior to treatment with single agent anti-PD1 antibody.UroGen Pharma  stock was up 6%, a day after the company said long-term data from a follow-up analysis of a phase 3 trial of its urothelial cancer therapy showed treatment response duration of nearly four years.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRTG","URGN","ASRV","BK4139","BK4211"],"gpt_icon":0},{"id":"2526614973","title":"BUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, American Express, Mondelez","url":"https://stock-news.laohu8.com/highlight/detail?id=2526614973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526614973?lang=en_us&edition=fundamental","pubTime":"2025-04-12 02:29","pubTimestamp":1744396169,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, American Express, MondelezEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nL6N3QP0HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTG","LU0158827781.USD","MDLZ","JOBY","MTSI","BW","LU1116320901.HKD","MPWR","FLNC","AXP","HII","LU2023250330.USD","SCCO","WFC","BHP.AU","IE00BN0W2W23.USD","BLK","LU0731783394.SGD","RIO.AU","ENZ","THS","CERT","LU1917777945.USD","ADI","CMTG","CNK","LU1430597077.USD","SDGR","TXN","BK","AKA","LU0964807845.USD","NEM","RIO.UK","LU1861214812.USD","EOG","WBD","MULN","XHG","ABSI","TREX","FCX","LUCY","BK4017","LU2506951792.HKD","SRPT","ENZB"],"gpt_icon":1},{"id":"2523500809","title":"Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500809","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500809?lang=en_us&edition=fundamental","pubTime":"2025-03-29 00:14","pubTimestamp":1743178491,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44540623/dow-tumbles-over-500-points-abacus-global-management-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","QID","USJW.SI","BK4173","PRTG","BK4139","BK4572","IE00B66KJ199.SGD","BK4122","IE00B19Z4B17.USD","IE0031619046.USD","BK4187","BK4007","PCOM","XTIA","TQQQ","DBVT","MNQmain","IE00B7SZL793.SGD","ABL","USAW.SI","NQmain","NVIW.SI","QLD","AIR","BK4134","SQQQ",".IXIC","TSYW.SI","MIST"],"gpt_icon":1},{"id":"2522680576","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2522680576","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522680576?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:25","pubTimestamp":1743164718,"startTime":"0","endTime":"0","summary":"Portage Biotech  shares rose 149% in recent Friday premarket activity, a day after it reported \"encouraging\" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with anti-PD-1 antibody.DBV Technologies  stock was up 53% after it said overnight it disclosed financing of up to $306.9 million to finance a peanut allergy patch for children aged four to seven years old.Top Wealth Group  shares climbed 32%, adding to the previous session's 13% gain.Hudson Pacific Properties  shares were up nearly 7% after BMO upgraded it to outperform from market perform and raised its price target to $5 from $4.American Resources  stock was nearly 1% higher after it said Thursday it signed a bond purchase deal with a sole institutional investor.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AREC","BK4156","BK7505","HPP","PRTG","DBVT","BK4223","BK4194","BK4212","BK4139","BK7141","TWG","HPP.AU"],"gpt_icon":1},{"id":"2522575361","title":"Investors Await Key Inflation Data as US Futures Decline Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2522575361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522575361?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:09","pubTimestamp":1743163757,"startTime":"0","endTime":"0","summary":"US stock futures were lower in Friday's premarket session as investors await key inflation data followed by consumer expectations and sentiment readings coming out later in the morning.The Dow Jones I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6116dc553b0f58a9a9560e0cd92ebdc2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","DBVT","PRTG","BK4211","BTBD","ISBC","BK4134","CRCT","BK4209","TWG","BK4191","BK4212","BK4139","XTIA"],"gpt_icon":0},{"id":"2522558220","title":"Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558220","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558220?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:02","pubTimestamp":1743112920,"startTime":"0","endTime":"0","summary":"Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.Portage said the data showed  both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PORT","PRTG","BK4139"],"gpt_icon":1},{"id":"2522537375","title":"Portage Reports 'Promising' Preclinical Results in Mesothelioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537375","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537375?lang=en_us&edition=fundamental","pubTime":"2025-03-28 05:11","pubTimestamp":1743109905,"startTime":"0","endTime":"0","summary":"Portage Biotech  reported late Thursday \"encouraging\" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with anti-PD-1 antibody.The data showed both single agent activity, and more than 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma, it said.\"This is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor,\" Portage said, adding that it's making preparations to start a first-in-human trial.The shares more than doubled in after-hours activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRTG","BK4139"],"gpt_icon":1},{"id":"2522347605","title":"BRIEF-Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7","url":"https://stock-news.laohu8.com/highlight/detail?id=2522347605","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522347605?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:46","pubTimestamp":1743108364,"startTime":"0","endTime":"0","summary":"BRIEF-Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7March 27 (Reuters) - Portage Biotech Inc PRTG.O:PORTAGE BIOTECH REPORTS PROMISING P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAPHMHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.portagebiotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.1484},{"period":"1year","weight":0.5948},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.221583},{"month":2,"riseRate":0.25,"avgChangeRate":-0.160379},{"month":3,"riseRate":0.2,"avgChangeRate":0.09221},{"month":4,"riseRate":0.6,"avgChangeRate":-0.068855},{"month":5,"riseRate":0.6,"avgChangeRate":0.296277},{"month":6,"riseRate":0.2,"avgChangeRate":-0.284423},{"month":7,"riseRate":0.4,"avgChangeRate":0.000618},{"month":8,"riseRate":0.4,"avgChangeRate":0.017196},{"month":9,"riseRate":0.4,"avgChangeRate":0.114966},{"month":10,"riseRate":0.25,"avgChangeRate":-0.059},{"month":11,"riseRate":0,"avgChangeRate":-0.24276},{"month":12,"riseRate":0.5,"avgChangeRate":0.057934}],"exchange":"NASDAQ","name":"Portage Biotech Inc.","nameEN":"Portage Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Portage Biotech Inc.(PRTG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Portage Biotech Inc.(PRTG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Portage Biotech Inc.,PRTG,Portage Biotech Inc.股票,Portage Biotech Inc.股票老虎,Portage Biotech Inc.股票老虎国际,Portage Biotech Inc.行情,Portage Biotech Inc.股票行情,Portage Biotech Inc.股价,Portage Biotech Inc.股市,Portage Biotech Inc.股票价格,Portage Biotech Inc.股票交易,Portage Biotech Inc.股票购买,Portage Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Portage Biotech Inc.(PRTG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Portage Biotech Inc.(PRTG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction